Welcome to N30 Pharma
A clinical stage biopharmaceutical company focused on modulating s-nitrosothiols to treat respiratory diseases.
NEWS
N30 Pharma Announces License Agreement With NitroMed, Inc.
News N30 Pharma Announces License Agreement With NitroMed, Inc.Monday October 29, 12:27 PM EST BOULDER, Co. -- N30 Pharma... LEARN MORE ›
N30 Pharma Announces Successful Initiation of Human Studies With N30-201
News N30 Pharma Announces Successful Initiation of Human Studies With N30-201Jan 28 2008, 1:00 AM EST BOULDER, Co -- N30 ... LEARN MORE ›
PRODUCTS
N30-201
N30-201 is a proprietary nebulized formulation of s-nitrosoglutathione (GSNO), an endogenous bronchodilatory molecule that serves as a crucial store of nitric oxide (NO) bioactivity in the human airway. LEARN MORE >
